MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities

Current Pathobiology Reports

Volumn 1, Issue 1, 2013, Pages 43-52

  Monroig, Paloma del C ^a   Calin, George A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Cancer; Diagnosis; Epigenetics; MicroRNA; Pathobiology; Therapy

Indexed keywords

EID: 84885860212     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0008-9     Document Type: Article

References (72)

1. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis function and decay. Nat Rev 11:597–610
2. Friedman RC, Farh KK, Burge CB et al (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105
3. Denli AM, Tops BB, Plasterk RH et al (2004) Processing of primary microRNAs by the Microprocessor complex. Nat Rev 432:231–235
4. Cheloufi S, Dos Santos CO, Chong MM et al (2010) A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465:584–589
5. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531
6. Inui M, Martello G, Piccolo S (2010) MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11(4):252–263
7. Wang Y, Lee CG (2009) MicroRNA and cancer—focus on apoptosis. J Cell Mol Med 13(1):12–23
8. •• Kasinski AL, Slack FJ (2011) Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev 11:849–864. This study discusses the progress using mouse models to understand the roles of miRNAs in cancer and the potential for manipulating miRNAs for cancer therapy.
9. • Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524–15529. This report presents evidence for the involvement of miRNA genes in human tumors, and provides further evidence of the significance of this growing family of regulatory genes.
10. Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101(9):2999–3004
11. Negrini M, Nicoloso MS, Calin GA (2009) MicroRNAs and cancer—new paradigms in molecular oncology. Curr Opin Cell Biol 21(3):470–479
12. Davalos V, Moutinho C, Villanueva A et al (2012) Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 31(16):2062–2074
13. Davis-Dusenbery BN, Hata A (2010) Mechanisms of control of microRNA biogenesis. J Biochem 148(4):381–392
14. Cheng CJ, Slack FJ (2012) The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J 18(3):232–237
15. Olive V, Bennett MJ, Walker JC et al (2009) miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23(24):2839–2849
16. Mu P, Han YC, Betel D et al (2009) Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23(24):2806–2811
17. Elmén J, Lindow M, Schütz S et al (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452(7189):896–899
18. • Esau C (2008) Inhibition of microRNA with antisense oligonucleotides. Methods Mol Biol 41(1):55–60. The focus of this review was the use of antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. It summarizes the employed antisense chemistries and their utility in designing antimiR oligonucleotides, and describes in vivo delivery strategies and approaches for assessment of miRNA inhibition and potential off-target effects.
19. •• Krützfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438(7068):685–689. The findings of this article show that antagomirs are powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy for silencing miRNAs in disease.
20. Fontana L, Fiori ME, Albini S et al (2008) Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 3(5):e2236
21. Ma L, Reinhardt F, Pan E et al (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28(4):341–347
22. •• Park JK, Kogure T, Nuovo GJ et al (2011) miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 71(24):7608–7616. These findings proved the preclinical efficacy of chol-anti-miR-221 in a valid orthotopic mouse model of hepatocellular carcinoma. Results suggest that targeting this miRNA serves a therapeutic benefit for patients with advanced disease.
23. Sapra P, Wang M, Bandaru R et al (2010) Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 29(2):97–112
24. Lu Y, Xiao J, Lin H et al (2009) A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 37(3):e24
25. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874
26. Stenvang J, Kauppinen S (2008) MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther 8(1):59–81
27. Ma L, Young J, Prabhala H et al (2010) miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12(3):247–256
28. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K et al (2012) Generation of miRNA sponge constructs. Methods Mol Biol 58(2):113–117
29. Gaur A, Jewell DA, Liang Y et al (2007) Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67(6):2456–2468
30. Kumar MS, Lu J, Mercer KL et al (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39(5):673–677
31. Merritt WM, Lin YG, Han LY et al (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641–2650
32. Love TM, Moffett HF, Novina CD (2008) Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol 121(2):309–319
33. Ibrahim AF, Weirauch U, Thomas M et al (2011) MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71(15):5214–5224
34. Kota J, Chivukula RR, O’Donnell KA et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005–1017
35. • Bader AG (2012) miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet 3:120. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.
36. Saito Y, Liang G, Egger G et al (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9(6):435–443
37. Huang YW, Liu JC, Deatherage DE et al (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69(23):9038–9046
38. Melo S, Villanueva A, Moutinho C et al (2011) Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA 108(11):4394–4399
39. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discovery 9:775–789
40. Bader AG, Brown D, Stoudemire J et al (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126
41. • Pereira DM, Rodrigues PM, Borralho PM et al (2012) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. This review focuses on in vivo strategies of miRNA modulator delivery in cancer models.
42. • Bonci D, Coppola V, Musumeci M et al (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14(11):1271–1277. This article proposed that miR-15a and miR-16 act as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion. Moreover, they suggest that the therapeutic implications found may be exploited for future treatment of prostate cancer.
43. Nadiminty N, Tummala R, Lou W et al (2012) MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE 7(3):e32832
44. Akao Y, Nakagawa Y, Hirata I et al (2010) Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther 17(6):398–408
45. Pramanik D, Campbell NR, Karikari C et al (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10(8):1470–1480
46. Rai K, Takigawa N, Ito S et al (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 10(9):1720–1727
47. Pecot CV, Calin GA, Coleman RL et al (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59–67
48. Gutiérrez-Puente Y, Tari AM, Ford RJ et al (2003) Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma 44(11):1979–1985
49. Landen CN Jr, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910–6918
50. Trang P, Wiggins JF, Daige CL et al (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19(6):1116–1122
51. de Antonellis P, Medaglia C, Cusanelli E et al (2011) MiR-34a targeting of notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS ONE 6(9):e24584
52. Wentz-Hunter KK, Potashkin JA (2011) The role of miRNAs as key regulators in the neoplastic microenvironment. Mol Biol Int. doi: 10.4061/2011/839872
53. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518
54. Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006
55. Lee Y, Ahn C, Han J et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956):415–419
56. •• Allegra A, Alonci A, Campo S et al (2012) Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 41(6):1897–1912. This manuscript emphasizes that miRNA profiling could improve the diagnosis of cancer and could predict patient outcome. Alterations in circulating miRNA may signal a predisposition to cancer, exalting the importance of these profiles as therapeutic targets in cancer patients.
57. National Cancer Institute (2012) Cancer statistics. Available at http://www.cancer.gov/statistics/find. Accessed December 2012
58. Boeri M, Verri C, Conte D et al (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 108(9):3713–3718
59. Shen J, Liu Z, Todd NW et al (2011) Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. doi: 10.1186/1471-2407-11-374
60. Wei J, Gao W, Zhu CJ et al (2011) Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30(6):407–414
61. Zheng D, Haddadin S, Wang Y et al (2011) Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4(6):575–586
62. Huang X, Ding L, Bennewith KL et al (2009) Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35(6):856–867
63. Center for Disease Control and Prevention (2012) Breast cancer. Available at http://www.cdc.gov/cancer/breast/. Accessed December 2012
64. Roth C, Rack B, Müller V et al (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12(6):R90
65. Heneghan HM, Miller N, Kerin MJ (2011) Circulating microRNAs: promising breast cancer biomarkers. Breast Cancer Res 13(1):402
66. Center for Disease Control and Prevention (2012) Colorectal cancer. Available at http://www.cdc.gov/cancer/colorectal/. Accessed December 2012
67. Cheng H, Zhang L, Cogdell DE et al (2011) Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6(3):e17745
68. Ng EK, Chong WW, Jin H et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10):1375–1381
69. National Cancer Institute (2012) SEER stat fact sheets: leukemia. Available at http://seer.cancer.gov/statfacts/html/leuks.html. Accessed December 2012
70. Moussay E, Wang K, Cho JH et al (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci USA 108(16):6573–6578
71. Lawrie CH, Gal S, Dunlop HM et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141(5):672–675
72. Tanaka M, Oikawa K, Takanashi M et al (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 4(5):e5532